Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALXN2350 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ALXN2350 | EXPERIMENTAL | Participants will receive one of three dose levels of ALXN2350 depending on the cohort. |
| Name | Type | Description |
|---|---|---|
| ALXN2350 | DRUG | ALXN2350 is a gene therapy product consisting of an AAV9 capsid containing BAG3 transgene. It is administered as a single intravenous (IV) infusion. |
Inclusion Criteria: * Pathogenic or likely pathogenic mutation in BAG3 * Medical history of diagnosis of DCM * Stable combination of HF SoC medications * Adequate acoustic windows for echocardiography * LVEF \> 15% and ≤ 45% at Screening by echocardiography * Diagnosis of chronic HF for at least 3 ...
ALXN2350 is an investigational small molecule being developed for BAG3 mutation associated dilated cardiomyopathy, a cardiovascular condition. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
ALXN2350 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. The drug is currently in Phase 1 clinical trials.
ALXN2350 is in Phase 1 clinical development. It is an investigational drug and has not yet been approved for any use. A Phase 1 trial is currently recruiting participants to evaluate the drug in adults with BAG3 mutation associated dilated cardiomyopathy.
ALXN2350 is being studied in a Phase 1 clinical trial with the identifier NCT07218887. This trial is titled 'ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy' and is currently recruiting participants in the United States, Italy, Spain, and the United Kingdom.
ALXN2350 is the primary name for this investigational drug. No alternative names have been reported for this asset in the available information. It is being studied under the clinical trial identifier NCT07218887.